Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma.

被引：1
|
作者：
Bair, A.
Hess, G.
Boni, J.
Offner, F.
机构：
[1] Pfizer Oncol, San Diego, CA USA
[2] Klinikum Johannes Gutenberg Univ, Med Klin & Poliklin 3, Mainz, Germany
[3] Pfizer Inc, Collegeville, PA USA
[4] Univ Ziekenhuis Gent, Ghent, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS222
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in the usual health care setting
    Krekeler, G.
    Herzberg, C.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONKOLOGIE, 2012, 35 : 44 - 44
  • [22] Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Hess, Georg
    Kang, Lisa
    Moran, Padraig J.
    BLOOD, 2011, 118 (21) : 1165 - 1165
  • [23] Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: A retrospective analysis
    Hess G.
    Coiffier B.
    Crump M.
    Gisselbrecht C.
    Offner F.
    Romaguera J.
    Kang L.
    Moran P.J.
    Experimental Hematology & Oncology, 4 (1)
  • [24] Phase II study of enzastaurin in the treatment of relapsed/refractory mantle cell lymphoma.
    Morschhausser, Frank
    Wolf, Martin
    Seymour, John
    Tilly, Herve
    Pfreundschuh, Michael
    Kluin-Nelemans, Hanneke
    Raemaekers, John
    van't Veer, Mars B.
    Milpied, Noel
    Cartron, Guillaume
    Pezzutto, Antonio
    Spencer, Andrew
    Darstein, Christelle
    Thornton, Donald
    Dreyling, Martin
    Reyes, Felix
    BLOOD, 2006, 108 (11) : 694A - 694A
  • [25] Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma
    Jurczak, Wojciech
    Ramanathan, Sundra
    Giri, Pratyush
    Romano, Alessandra
    Mocikova, Heidi
    Clancy, Jill
    Lechuga, Mariajose
    Casey, Michelle
    Boni, Joseph
    Giza, Agnieszka
    Hess, Georg
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 670 - 678
  • [26] Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.
    Zaja, Francesco
    De Luca, Stefano
    Vitolo, Umberto
    Orsucci, Lorella
    Levis, Alessandro
    Salvi, Flavia
    Gargantini, Livio
    Ravelli, Erika
    Tucci, Alessandra
    Bottelli, Chiara
    Balzarotti, Monica
    Santoro, Armando
    Brusamolino, Ercole
    Bonfichi, Maurizio
    Di Rocco, Alice
    Stelitano, Caterina
    Baldini, Luca
    Pileri, Stefano Aldo
    Volpetti, Stefano
    Ciccone, Giovannino
    Ferranti, Antonella
    Fanin, Renato
    BLOOD, 2009, 114 (22) : 683 - 683
  • [27] OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Le Gouill, Steven
    Davies, Andrew
    Bouabdallah, Kamal
    Chiron, David
    Rule, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] TEMSIROLIMUS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: DOES PROGNOSTIC RISK AFFECT OUTCOMES?
    Hess, G.
    Kang, L.
    Moran, P.
    HAEMATOLOGICA, 2012, 97 : 101 - 101
  • [29] TREATMENT OF PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA WITH TEMSIROLIMUS: ADVERSE EVENT PROFILES OF HIGH AND LOW DOSE REGIMENS ARE SIMILAR
    Herbrecht, R.
    Romaguera, J.
    Verhoef, G.
    Crump, M.
    Coiffier, B.
    Strahs, A.
    Galand, L.
    Binlich, F.
    Hewes, B.
    Hess, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 229 - 229
  • [30] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
12345